|Application ||WB, FC, E|
|Other Accession||Q6P2L7, NP_816929.1|
|Calculated MW||48864 Da|
|Other Names||Protein CASC4, Cancer susceptibility candidate gene 4 protein, CASC4|
|Target/Specificity||This CASC4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 336-365 amino acids from the C-terminal region of human CASC4.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CASC4 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Membrane; Single-pass type II membrane protein|
Provided below are standard protocols that you may find useful for product applications.
The increased expression level of this gene is associated with HER-2/neu proto-oncogene overexpression. Amplification and resulting overexpression of this proto-oncogene are found in approximately 30% of human breast and 20% of human ovarian cancers. Further characterization of the product of this gene may yield insight into the fundamental biology and pathogenetic effects of HER-2/neu overexpression in human breast and ovarian cancer cells. Alternatively spliced variants encoding different isoforms have been identified for this gene.
Lamesch, P., et al. Genomics 89(3):307-315(2007)
Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)
Sato, T., et al. Onkologie 26(3):268-271(2003)
Scheer, M., et al. Mund Kiefer Gesichtschir 7(3):138-145(2003)
Oh, J.J., et al. Nucleic Acids Res. 27(20):4008-4017(1999)